Session » Immunological Complications of Medical Therapy Poster
- 10:30AM-12:30PM
-
Abstract Number: 1988
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
- 10:30AM-12:30PM
-
Abstract Number: 1981
Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments
- 10:30AM-12:30PM
-
Abstract Number: 1998
Association Between Small Interfering RNA Therapy and Autoimmune Diseases: U.S. Prospective Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 1994
Clinical Patterns and Long-term Outcomes of Arthritis Triggered by Immune Checkpoint Inhibitors. A Multicenter Study
- 10:30AM-12:30PM
-
Abstract Number: 1982
Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital
- 10:30AM-12:30PM
-
Abstract Number: 2001
Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis
- 10:30AM-12:30PM
-
Abstract Number: 2003
Cumulative Incidence of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis in Lung Cancer Patients with and Without Hip Osteoarthritis and Impacts on Survival
- 10:30AM-12:30PM
-
Abstract Number: 1986
Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 1999
Effects of JAK Inhibitors on Subsets of the Innate Immune System
- 10:30AM-12:30PM
-
Abstract Number: 1980
Efficacy and Safety of Methotrexate in Immune Checkpoint Inhibitor-induced Arthritis: A Retrospective Longitudinal Monocentric Study
- 10:30AM-12:30PM
-
Abstract Number: 1997
Features of interleukin-1 and interleukin-6 Inhibitor (IL-1i/IL-6i) Related Severe Delayed Adverse Reactions in Subjects with or Without Reaction-risk Associated HLA-DRB1*15
- 10:30AM-12:30PM
-
Abstract Number: 1992
Gout FlaresFollowingImmune Checkpoint Inhibitors Treatment
- 10:30AM-12:30PM
-
Abstract Number: 1996
Granulomatous Reactions in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Literature Review
- 10:30AM-12:30PM
-
Abstract Number: 1989
Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 1990
Human Umbilical Cord Mesenchymal Stem Cell-derived Microvesicles Alleviate Pulmonary Fibrosis by Inhibiting Monocyte-macrophage Migration Through ERK1/2 Signaling-mediated Suppression of CCL2 Expression
- 10:30AM-12:30PM
-
Abstract Number: 1993
Identification of Elevated Soluble Factors in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Their Association with Severity and Persistence
- 10:30AM-12:30PM
-
Abstract Number: 1983
Immune Checkpoint Inhibitor Associated Vasculitis and Polymyalgia Rheumatica: A Systematic Review
- 10:30AM-12:30PM
-
Abstract Number: 2000
Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
- 10:30AM-12:30PM
-
Abstract Number: 1991
Initial Corticosteroid Dosing and Effects on Disease Activity, Survival, and Tumor Progression in Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 2002
Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 1978.5
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
- 10:30AM-12:30PM
-
Abstract Number: 2004
Rheumatic Complications Post-CAR-T Cell Therapy. Experience of a Single Center
- 10:30AM-12:30PM
-
Abstract Number: 1979
Safety and Effectiveness of Immune Checkpoint Inhibitor Therapy in Patients with Pre-existing Autoimmune Disease
- 10:30AM-12:30PM
-
Abstract Number: 1985
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
- 10:30AM-12:30PM
-
Abstract Number: 1995
Use of Abatacept for the Treatment of Severe Immune-related Adverse Events from Immune Checkpoint Inhibitors for Cancer: A Case Series
- 10:30AM-12:30PM
-
Abstract Number: 1984
Use of ICD Codes for the Identification of Patients with Immune Checkpoint Inhibitor Induced Inflammatory Arthritis